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ABSTRACT: 
Tuberculosis and HIV are arguably South Africa’s largest and most important health issues. With 
drug-resistant strains of tuberculosis on the increase and little research on new drugs, there is an 
urgent need for research around the drugs presently available to ensure their optimal use and to 
minimise their sometimes serious and significant side effects.  
Treatment of drug-resistant tuberculosis is expensive and lengthy, and is complicated by a 
limited choice of drugs with lower efficacies and higher toxicities. Treatment is further 
complicated in patients with HIV due to several factors including drug interactions. While some 
authors suggest that HIV and malabsorption might be associated with poor clinical outcomes, 
other researchers have found no link. Patients may benefit from Therapeutic Drug Monitoring in 
order to ensure that their doses of antituberculosis drugs are reaching the required minimum 
effective concentrations, without attaining toxic levels in the plasma which may cause unpleasant 
side effects. There is little research concerning drug levels in HIV patients with TB in South 
Africa, let alone in patients with drug-resistant forms of tuberculosis, and there are no studies in 
this country that use Liquid Chromatography-Mass Spectrometry to investigate the plasma levels 
of pyrazinamide in patients with MDR-TB.   
This study aimed to investigate whether or not there is a difference in the pharmacokinetics of 
PZA in MDR-TB patients with HIV, and those without HIV infection. It also aimed to establish 
whether LC-MS could be used to study the levels of pyrazinamide in the plasma of patients with 
multidrug-resistant tuberculosis with and without concurrent HIV infection. The plasma levels of 
pyrazinamide in 32 MDR-TB patients (23 HIV negative and 9 HIV positive), were successfully 
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analysed using LC-MS, and the pharmacokinetics of PZA in these 2 populations was described. 
It was established that the Tmax of pyrazinamide was significantly higher in HIV-negative 
patients than in HIV-positive patients. Although there was a difference between the Ka in the two 
populations, this difference did not quite reach statistical significance. There were no statistically 
significant differences between HIV-negative and HIV-positive patients with regards to the other 
pharmacokinetic parameters investigated.  
Our findings established that there was little evidence to suggest that there is a difference 
between the pharmacokinetics of the antimycobacterial drug pyrazinamide in HIV-positive 
patients and that in HIV-negative patients. We were also able to successfully develop and 
validate an assay for the analysis of PZA in plasma using LC-MS, and this finding could be very 
valuable for further studies. 
Although our study failed to prove this, the possibility still exists that HIV-positive patients 
could exhibit altered kinetics of antiTB drugs and this has not been fully investigated in South 
Africa. The clinical impact of low plasma levels of antimycobacterial drugs is still largely 
unexplored and further research with larger sample sizes should be done in order to establish 
which factors may contribute to low plasma levels of anti-tuberculosis drugs in MDR-TB 
patients, and whether or not these low levels are increasing the risk of treatment failure or other 
poor clinical outcomes.  
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CHAPTER ONE: 
INTRODUCTION 
 
Tuberculosis (TB) is an ancient disease that is reappearing at increasingly alarming rates, 
especially in South Africa. Even more concerning, is the emergence of Multidrug-Resistant 
Tuberculosis (MDR-TB) and Extensively Drug-Resistant Tuberculosis (XDR-TB).  
Recently, researchers in India described patients with a terrifying new disease: Totally Drug-
Resistant Tuberculosis (TDR-TB), where patients are resistant to all available anti-tuberculosis 
treatments [Udwadia et al, 2012]. Similar cases were reported in Iran by Velayati et al 
[2009:420].  While cure rates for drug-susceptible tuberculosis are generally high - 79% in 2010 
in South Africa [WHO, 2012a], the estimated cure rate for MDR-TB worldwide in 2009 was only 
around 48% [WHO, 2013a]. The cure rate for MDR-TB in South Africa is also estimated to be 
less than 50% [DOH, 2009a:ii].  
Currently, according to the South African Department of Health (DOH) guidelines, 
pyrazinamide (PZA) forms part of the regimen for the treatment of both drug-susceptible 
tuberculosis (DS-TB) and MDR-TB  [DOH, 2009 b; DOH, 2011]. It is used together with other 
antimycobacterial drugs, as resistance develops rapidly when used as monotherapy.  
There are several studies concerning the pharmacokinetics of PZA in patients with and without 
tuberculosis, but PZA’s pharmacokinetics in HIV (human immunodeficiency virus) positive 
patients is not fully described [Perlman et al, 2004], and there are seemingly no studies in South 
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Africa that demonstrate the pharmacokinetics in patients with drug-resistant TB, and specifically 
drug-resistant TB and HIV infection.  
The aim of this study was to use liquid chromatography-mass spectrometry (LC-MS) to 
investigate PZA plasma concentrations, to describe the pharmacokinetics of PZA in patients with 
MDR-TB and in those with MDR-TB and HIV infection, and to see if there may be differences 
between the groups.  This was achieved by obtaining blood samples from 32 MDR-TB patients 
both with, and without HIV, and using LC-MS to analyse the levels of PZA within these 
samples. This information was then used to conduct pharmacokinetic analysis of the 2 patient 
groups, and the results were compared statistically.   
Information gathered in this study could shed new light on the characteristics of pyrazinamide 
pharmacokinetics in MDR-TB patients and give a better understanding of whether or not these 
patients may be subject to subtherapeutic drug levels. This information could be especially 
valuable in patients with HIV infection who may be more susceptible to decreased serum 
concentrations of anti-TB drugs, possibly due to impaired absorption [Yew, 2001; Li et al, 2004; 
Peloquin, 1998] or who may be taking antiretroviral drugs which may interact with, or alter the 
pharmacokinetics of antimycobacterial drugs. [Nuermberger and Grosset, 2004; Coyne et al, 
2009; de Jong et al, 2004].  
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CHAPTER TWO: 
 LITERATURE REVIEW 
 
2.1 Tuberculosis: 
2.1.1 History, epidemiology, and symptoms 
Tuberculosis is an infectious disease caused by the bacterium Mycobacterium tuberculosis. The 
tubercule bacillus was first discovered by Nobel Laureate Robert Koch in 1882, and while it 
typically infects the lungs, it may infect almost any area in the body. The infection is spread by 
the inhalation of bacteria in small droplet nuclei which become airborne when a TB patient 
coughs, sneezes or talks. Common symptoms include chronic cough, fever, night sweats and 
weight loss [WHO, 2013b].  
Mycobacterium tuberculosis (MTB) has killed more people than any other single infection in 
history, and there is ever increasing drug resistance, yet few new drugs are being brought onto 
the market to treat these resistant strains. In the 1970’s and 1980’s, TB rates in the USA were 
declining, and so funding for research was cut drastically. TB rates then started to increase, with 
many cases of extra-pulmonary TB appearing. This was as a result of the rapidly emerging 
HIV/AIDS pandemic. A study presented at the annual joint meeting of The American Thoracic 
Society and The American Lung Association in 1984 reported that: “this new disease ‘AIDS’ 
was “fueling the latent fire of a familiar old infection” [in Reichman and Hopkins Tanne, 2002].  
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TB caused 1,4 million deaths worldwide in 2011 alone [WHO, 2013b], with 25000 South 
Africans dying of the disease in 2011 [WHO, 2012a]. South Africa recorded 325321 new cases 
of TB and 45915 re-treatment cases in 2011; the cure rate for re-treatment TB in 2010 was only 
35% [WHO, 2012a]. 
 
2.1.2. Treatment: 
Treatment for DS-TB in South Africa consists of chemotherapy for six months with a 
combination of four oral antimycobacterial drugs, namely; rifampicin (RIF), isoniazid (INH), 
pyrazinamide (PZA) and ethambutol (EMB). This consists of an intensive phase of RIF, INH, 
PZA and EMB for 2 months followed by a continuation phase of RIF and INH for 4 months. In 
retreatment cases, therapy may also include the use of the aminoglycoside streptomycin by 
intramuscular injection [DOH, 2009 b]. 
 
2.2 Multi-drug resistant tuberculosis: 
2.2.1 Definition: 
MDR-TB is defined as TB that is resistant to rifampicin and isoniazid, with or without resistance 
to other antimycobacterial drugs [DOH, 2009b; Sharma et al, 2006].  
 
 
 
 
 
7 
 
2.2.2 History and Epidemiology: 
According to the World Health Organisation, there were an estimated 500 000 new MDR-TB 
cases worldwide in 2011, around 3.7% of new TB cases were MDR while around 20% of re-
treatment cases were classified as MDR-TB. Approximately 60% of the world’s MDR-TB cases 
occur in the following countries: Brazil, China, India, the Russian Federation and South Africa 
[WHO, 2013a]. 
With the cost of treating MDR-TB at about 25 times higher than that of DS-TB [Pooran et al, 
2013], and cure rates as low as 48% [WHO, 2013a].  MDR-TB is a health crisis with far-reaching 
economic and social consequences.   
There are two mechanisms by which a patient may acquire MDR-TB; the first is primary 
resistance whereby a patient who has not previously been treated for TB becomes infected with a 
drug-resistant strain of Mycobacterium tuberculosis, the second is acquired resistance, where a 
patient has been treated for TB on one or more occasions and hence where resistance is likely to 
have been caused by an insufficient amount of one or more antimycobacterial drugs [Friedland, 
2007a]. This insufficient amount or improper use may be caused by poor patient compliance, 
poor quality medicines, or the administration of inappropriate treatment regimens, for example in 
areas with poor TB control programs [WHO, 2013b]. Inadequate drug levels select for resistant 
mutants, and once patients have resistance to one of the drugs, they are more likely to develop 
resistance to other drugs too [Friedland, 2007a]. Researchers in Kazakhstan identified 
alcoholism, smoking, increased number of previous TB treatments as well as irregular treatment, 
as being risk factors for acquired DR-TB [Barroso et al, 2003]. 
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2.2.3 Treatment: 
The treatment of drug-resistant TB is much more complicated than the treatment of drug-
sensitive TB. It involves the use of drugs that are much more expensive, more toxic, less 
effective and less tolerable [WHO, 2013a; Kahana, 1996]. It may also include the use of 1
st
 line 
drugs to which the patient’s isolate is still sensitive, for example PZA, ethambutol, or even 
isoniazid. MDR-TB cure rates are lower [WHO, 2013a] and treatment far more expensive than 
that of DS-TB [MSF, 2011]. In addition to this, the duration of treatment is much longer, usually 
at least 18-24 months in MDR-TB as opposed to 6 months in drug-sensitive TB. In South Africa, 
the national guidelines [DOH, 2011] recommend a 5-drug regimen during a 6-month intensive 
phase followed by a 4-drug regimen during the18 month continuation phase. These regimens are 
shown below in Table 3 and Table 4. Although ideally these patients are hospitalized for at least 
part of their treatment, a lack of resources amongst other reasons means that some patients 
undergo “Clinic-based care” instead.  
Table 1: Standardised National MDR-TB Treatment Regimen for Adults and Adolescents 
(Intensive phase) [DOH, 2011]. This is taken at least six days a week, for at least 6 months, 
guided by TB Culture Conversion 
Patient Weight:   Drug:     Dose: 
<33kg     Kanamycin    15-20mg/kg 
Moxifloxacin    400mg 
     Ethionamide    15-20mg/kg 
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     Terizidone    15-20mg/kg 
     Pyrazinamide    30-40mg/kg 
33-50kg    Kanamycin    15-20mg/kg 
Moxifloxacin    400mg 
     Ethionamide    500mg 
     Terizidone    750mg 
     Pyrazinamide    1000-1750mg 
51-70kg    Kanamycin    1000mg 
Moxifloxacin    400mg 
     Ethionamide    750mg 
     Terizidone    750mg 
     Pyrazinamide    1750-2000mg 
>70kg     Kanamycin    1000mg  
Moxifloxacin    400mg 
     Ethionamide    750-1000mg 
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     Terizidone    750-1000mg 
     Pyrazinamide    2000-2500mg 
 
Table 2: Standardised National MDR-TB Treatment Regimen for Adults and Adolescents 
(Continuation phase) [DOH, 2011]. 
This is taken at least 6 times a week, for at least 18 months after TB Culture Conversion: 
Patient Weight:   Drug:     Dose: 
<33kg     Moxifloxacin    400mg 
     Ethionamide    15-20mg/kg 
     Terizidone    15-20mg/kg 
     Pyrazinamide    30-40mg/kg 
33-50kg    Moxifloxacin    400mg 
     Ethionamide    500mg 
     Terizidone    750mg 
     Pyrazinamide    1000-1750mg 
51-70kg    Moxifloxacin    400mg 
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     Ethionamide    750mg 
     Terizidone    750mg 
     Pyrazinamide    1750-2000mg 
>70kg     Moxifloxacin    400mg 
     Ethionamide    750-1000mg 
     Terizidone    750-1000mg 
     Pyrazinamide    2000-2500mg 
 
The following drugs are used in the treatment of drug-resistant TB in South Africa [DOH, 2011]: 
amikacin/kanamycin, PZA, ethambutol, capreomycin, ethionamide, 
moxifloxacin/ofloxacin/levofloxacin, cycloserine/terizidone and para-aminosalicylic acid (PAS). 
Other drugs that may be used in the treatment of drug-resistant TB are thioacetazone, 
clofazimine, amoxycillin-clavulanate, clarithromycin, azithromycin, rifabutin, rifapentine, high-
dose isoniazid, imipenem and linezolid [DOH, 2011]. 
The diagnosis of DR-TB is also costly and more complicated [Friedland, 2007a]. Treatment must 
be individualized and tailored according to the susceptibility of the patient’s isolate. Resources 
are needed to provide adherence counseling, psychosocial support and management of side 
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effects. Second-line drugs are expensive and not always easy to source, and their quality may be 
questionable [MSF, 2011].  
Research into the development of new anti-TB drugs has largely been neglected as the disease 
mainly affects developing countries and is therefore not a very lucrative market for 
pharmaceutical companies. Drugs used for treating MDR-TB have limited efficacy with success 
rates around 80%, at best, and the international organization MSF feels that in the absence of 
newer, better therapies, there is an urgent need to improve existing regimens used for MDR-TB; 
to maximize their effectiveness while making them more tolerable and minimizing their side 
effects [MSF, 2011].   
Side effects of anti-TB drugs may include; nausea, vomiting, diarrhea, vertigo, hearing loss, joint 
pain, peripheral neuropathy, hepatotoxicity, depression and hallucinations [DOH, 2009b; MSF, 
2011].  In a study done in Nepal [Koju et al, 2005], which looked at the occurrence of side 
effects of anti-TB drugs, it was reported that 80% of patients experienced at least one type of 
side effect, with 34.29% experiencing major side effects. Female gender, history or alcohol 
abuse and positive sputum smear were factors associated with an increased risk for occurrence of 
these side effects. Pande et al [1996] looked at the risk factors associated with hepatotoxicity in 
patients taking antimycobacterial drugs for the treatment of TB. They found that increased 
alcohol intake, hypoalbuminaemia, age and advanced disease were all factors associated with an 
increased incidence of hepatitis. 
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2.3 Pharmacology of anti-tuberculosis drugs: 
2.3.1 Rifampicin 
Rifampicin is bactericidal for intra- and extra cellular bacteria and inhibits bacterial RNA 
synthesis by interfering with DNA-dependant polymerase [Chambers, 2004]. The oral 
bioavailability is reduced by food and by first-pass metabolism. It is well distributed, 
with cerebrospinal fluid (CSF) concentrations reaching 10-20% of the plasma 
concentrations. Protein binding is 80-90% and rifampicin has a half-life of 2.5hrs (which 
is increased in hepatic disease). It is metabolized rapidly in the liver and undergoes 
autoinduction. Rifampicin and its active deacetylated metabolite are eliminated chiefly 
via the biliary-faecal route and 60-65% is excreted unchanged in the faeces, the 
remainder in the urine [Rossiter, 2010].  
Adverse effects of rifampicin include hepatotoxicity (which is increased in the prescence 
of other hepatotoxic drugs like isoniazid), gastro-intestinal disturbances such as nausea, 
vomiting and diarrhoea, central nervous system (CNS) disturbances and hypersensitivity 
reactions. The drug may cause a red-orange discolouration of body fluids such as urine 
and tears [Chambers, 2004]. Rifampicin should be used with caution in patients with pre-
existing hepatic dysfunction and porphyria, and in patients taking other hepatotoxic drugs 
or alcohol. Rifampicin may interact with many drugs due to the fact that it is a potent 
inducer of certain enzymes in both the liver and intestine. The levels of these drugs may 
be decreased and may drop below therapeutic levels, requiring dosage adjustment Drugs 
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involved include: protease inhibitors (PIs), non-nucleoside reverse transcriptase inhibitors 
(NNRTIs), phenytoin, warfarin, oral contraceptives, and digoxin. [Rossiter, 2010]. 
The usual adult dose is 10mg/kg orally (PO) or by intravenous injection (IVI) as a single 
daily dose [Chambers, 2004]. In patients with liver impairment, the total daily dose 
should not exceed 8mg/kg and in paediatrics the usual dose is 10mg/kg/day (although this 
may be increased to 20mg/kg/day in the treatment of miliary TB and TB meningitis 
[Rossiter, 2010]. 
  
2.3.2 Isoniazid 
Isoniazid is bactericidal for intra- and extracellular mycobacteria and exerts its action by 
inhibiting mycobacterial cell wall synthesis [Chambers, 2004]. As well as being used in 
the treatment of TB, it is used prophylactically in IPT (Isoniazid Preventative Therapy). 
Oral absorption of isoniazid is good, although this is decreased when taken 
simultaneously with food or antacids, and by first-pass metabolism [Rossiter, 2010]. It is 
distributed widely, including in the CNS and has a half-life of 1-6 hours. It undergoes 
metabolism in the liver, mainly by acetylation and some unchanged isoniazid and 
inactive metabolites are excreted in the urine [Chambers, 2004].  
Isoniazid is hepatotoxic and may cause transient elevation of liver enzymes. It is also 
neurotoxic and may cause peripheral neuropathy. Because of this, pyridoxine is usually 
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given in conjunction with isoniazid therapy. Skin rashes, gastrointestinal disturbances and 
heamatological abnormalities have also been known to occur [Chambers, 2004]. 
Due its possible hepatotoxicity, caution should be exercised in patients with pre-existing 
liver impairment or porphyria, and in patients taking other potentially hepatotoxic drugs 
or alcohol. Drug interactions are common with isoniazid use due to the fact that isoniazid 
is an inhibitor of certain cytochrome P450 enzymes. Isoniazid will inhibit the metabolism 
of these drugs and hence their doses may need to be reduced in order to prevent toxicity. 
Drugs involved include: phenytoin, carbamazepine, warfarin and theophylline. The 
concomitant use of isoniazid with rifampicin, paracetamol or alcohol may potentiate 
hepatotoxic effects. In adults, isoniazid is dosed at 5mg/kg daily as a single oral dose and 
in paediatrics between 5 and 10mg/kg/day. In TBM (TB meningitis) and miliary TB, 
20mg/kg/day may be given. When INH is given as prophylaxis (IPT), the dose is 
10mg/kg daily (maximum 300mg/day) [Rossiter, 2010].  
 
2.3.3 Ethambutol 
Ethambutol is bacteriostatic, but may be bactericidal at higher doses. It is hypothesized 
that it exerts its effect by inhibiting ribonucleic acid (RNA) synthesis in actively dividing 
mycobacteria [Rossiter, 2010]. It is used in the treatment of DS-TB and DR-TB, and has 
low toxicity and good tolerance [DOH, 2011]. Ethambutol is well distributed except in 
the CSF. It has an elimination half-life of 3-4 hours in healthy patients, which is 
increased in patients with renal impairment. Approximately 15% is metabolized in the 
 
 
 
 
16 
 
liver, and it is eliminated chiefly by the excretion of the unchanged drug in the urine. The 
most common side effects experienced are optic neuritis and hyperuricaemia (which may 
cause arthralgia and gout). Other less common side effects are gastrointestinal 
disturbances, peripheral neuropathy and skin rashes. The use of ethambutol is contra-
indicated in patients with advanced renal failure and in those with optic neuritis. It should 
be used with caution in patients with renal impairment and eye defects.  Ethambutol is 
not recommended for use in children younger than 8 years old except in severe cases 
where the benefit outweighs the risk. Ethambutol interacts with PZA and thiazide 
diuretics causing an increased risk of elevated serum urate levels. When used with other 
neurotoxic drugs, the risk of optic and peripheral neuritis is increased [Rossiter, 2010].  
In adults and paediatrics, ethambutol is given at a dose of 15mg/kg orally once daily, 
with doses up to 25mg/kg being used for TB meningitis [Chambers, 2004]. In geriatric 
patients, the lowest dosing range should be used (maximum 15mg/kg daily) and in 
patients with renal impairment the dosage intervals should be increased [Rossiter, 2010]. 
 
2.3.4 Streptomycin/Amikacin/Kanamycin 
Streptomycin was the first antimycobacterial drug to be discovered. Aminoglycosides 
exert their antimicrobial action by inhibiting bacterial protein synthesis by binding to the 
30S ribosomal subunit and are bactericidal against actively dividing bacteria [DOH, 
2011].  
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Following intramuscular (IM) injection, peak concentrations of aminoglycosides in the 
plasma are reached in approximately 30 – 90 minutes. This class of drugs exhibits 
concentration-dependant killing and a significant post-antibiotic effect; therefore it is 
recommended that they be given as a single daily dose [Chambers, 2004]. 
Aminoglycosides are cleared via the kidneys and have a half-life of approximately 2-3 
hours in patients with normal renal function. Therapeutic drug monitoring is useful in 
patients with renal impairment so as to avoid or minimise accumulation and toxicity, 
dosing intervals may need to be increased depending on plasma levels dose [Rossiter, 
2010.  
The most common and serious side effects of aminoglycosides are nephrotoxicity and 
ototoxicity [Chambers, 2004]. Nephrotoxicity is more likely in patients with renal 
impairment or those taking other nephrotoxic agents concurrently. The use of 
aminoglycosides with other nephrotoxic or ototoxic drugs is not recommended due to the 
additive potential for toxic effects. When used with neuromuscular blocking agents, 
blockade may be potentiated. Hypersensitivity reactions and CNS effects such as 
headaches may also occur. Aminoglycosides are contra-indicated in patients who are 
hypersensitive to them and they are not recommended for use in pregnancy as they cross 
the placenta and may cause fetal ototoxicity. They should be used in caution in patients 
with renal impairment, hearing impairment and myasthenia gravis [Rossiter, 2010].  
The usual adult dose for aminoglycosides is 15mg/kg. In patients with renal impairment, 
the dosing interval should be prolonged and the dose reduced according to plasma levels. 
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Streptomycin is given by IM injection only, amikacin and kanamycin may be given IM or 
IV [Rossiter, 2010]. 
 
2.3.5 Capreomycin 
Capreomycin is a cyclic polypeptide that inhibits protein synthesis in mycobacteria. It is 
given by intramuscular injection. A daily dose of 1g yields plasma concentrations of 
approximately 10mcg/ml [Chambers, 2004]. Capreomycin is classed as having moderate 
tolerance and medium toxicity, and its use is commonly limited by its nephrotoxicity) 
[DOH, 2011]. It is also frequently ototoxic, and may also cause hypersensitivity reactions 
such as a skin rash. Capreomycin should be used with caution in patients with renal or 
hearing impairment, and in patients taking aminoglycosides [DOH, 2011].  
The adult dose for capreomycin is 15mg/kg daily IMI (maximum 20mg/kg/day) [DOH, 
2011]. In patients older than 50 years, this is decreased to10mg/kg/day (maximum 
750mg/day). Paediatric patients are dosed at 15-30mg/kg/day (maximum 1g/day), in 
patients with renal impairment the dose should be decreased, and the dosing interval 
should be increased  [Chambers, 2004].  
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2.3.6 Ethionamide 
Ethionamide is bacteriostatic, but bactericidal at higher concentrations [DOH, 2011]. It is 
a synthetic thiocarbamide derivative of isonicotinic acid. Ethionamide is widely 
distributed, including into the CNS. It has a half-life of 3 hours and is metabolized mainly 
in the liver. Active and inactive metabolites and approximately 1% of the unchanged drug 
is excreted into the urine [Rossiter, 2010]. 
 Gastrointestinal disturbances are the most common, particularly nausea, vomiting and 
metallic taste. This may be alleviated somewhat by dividing the total daily dose. CNS 
effects such as psychosis, depression and anxiety may also occur. The use of ethionamide 
is contra-indicated in patients hypersensitive to the drug, as well as patients with severe 
hepatic dysfunction and porphyria. Caution should be exercised when using ethionamide 
in patients with a history of psychiatric illness, epilepsy, diabetes or hypothyroidism 
[Rossiter, 2010].  
When ethionamide is used with isoniazid, there is an increased risk of neurological side 
effects. When it is used with cycloserine or terizidone, there is an increased risk of CNS 
side effects. In adults and paediatrics older than 10 years, the usual dose is 15-20mg/kg 
daily as a single oral dose (maximum 1g/day). Patients with renal impairment with a 
glomerular filtration rate (GFR) less than 10ml/min should be given 50% of the normal 
dose. Paediatrics less than 10 years are given 10-15mg/kg daily (this may be increased to 
20mg/kg daily in miliary TB or TB meningitis)[ Rossiter, 2010].  
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2.3.7 Moxifloxacin/Ofloxacin/Levofloxacin 
Fluoroquinolones are bactericidal and exert their effect by inhibiting deoxyribonucleic 
acid (DNA) gyrase and therefore bacterial DNA production [Chambers, 2004]. 
Moxifloxacin is preferred in the treatment of MDR and XDR-TB but ofloxacin and 
levofloxacin are preferred in patients younger than 8 years old [DOH, 2011].  
Fluoroquinolones are well absorbed following oral administration and distributed widely 
in the tissues. They are excreted renally. The half-life of ofloxacin and levofloxacin is 5-7 
hours while the half-life of moxifloxacin is 9-10 hours [Chambers, 2004]. The 
fluoroquinolones are generally well tolerated with common side effects being 
gastrointestinal such as nausea and diarrhoea. Quinolones are contraindicated in patients 
who have a known allergy or sensitivity to them. Caution should be exercised when using 
them in patients with hepatic or renal impairment or in patients under 18 years old as they 
may damage growing cartilage. They are not recommended for use in pregnant or 
lactating women [Rossiter, 2010]. Fluoroquinolones should not be taken with antacids or 
minerals such as calcium, iron or magnesium as they may complex with the drug and 
reduce absorption [Chambers, 2004].  Levofloxacin is given to adults in a dose of 7.5-
10mg/kg daily (maximum 1000mg/day) and to paediatric patients younger than 5 years 
old in a dose of 10mg/kg twice daily. Paediatric patients older than 5 years are given 
10mg/kg once daily. The adult dose for moxifloxacin is 400mg daily (orally or IV), and 
the dose for children is 7.5mg-10mg/kg daily. Ofloxacin is dosed at 800mg daily for 
adults (oral or IV) [DOH, 2011]. 
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2.3.8 Terizidone/Cycloserine 
Terizidone is a cycloserine derivative but has a lower incidence of side effects than 
cycloserine. It is a combination of 2 molecules of cycloserine and therefore is widely 
regarded as the same drug effects [DOH, 2011]. It is bacteriostatic and inhibits 
mycobacterial cell wall synthesis by interfering with peptidoglycan pentapeptide 
production [Chambers, 2004].  Terizidone shows good absorption and distribution into 
tissues and fluids including the CSF [Rossiter, 2010]. It is metabolized by the kidneys 
and the majority of a dose is excreted in active form into the urine. Terizidone commonly 
causes a range of neurological side effects such as seizures, psychosis, depression, 
anxiety, drowsiness, tremor and dizziness. These are most common in patients with renal 
impairment or those receiving high doses [Chambers, 2004]. High dose pyridoxine 
(150mg) should be given concomitantly to minimize neurological side effects [DOH, 
2011]. Terizidone use is contra-indicated in patients with porphyria, psychosis, 
depression, epilepsy and severe renal impairment. It is given to adults at a dose of 10-
20mg/kg daily orally (maximum 750mg/day). The dosing interval should be prolonged 
for patients with renal impairment [Rossiter), 2010]. 
 
2.3.9 Para-aminosalicylic acid (PAS) 
PAS is bacteriostatic and acts by inhibiting mycobacterial folate synthesis. PAS is readily 
absorbed after oral administration and is distributed widely in tissues and fluids except 
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the CSF. It has a half-life of about 1 hour and is excreted in the urine both as the 
unchanged drug and its metabolites [Chambers, 2004].  
It frequently causes gastrointestinal disturbances such as anorexia, nausea and diarrhoea, 
but is generally classed as having low toxicity. It may also cause hepatitis, 
hypothyroidism, goitre and a malabsorption syndrome [DOH, 2011]. 
PAS is contra-indicated in patients with severe renal insufficiency.  PAS inhibits the 
absorption of rifampicin and digoxin from the gastro-intestinal tract and therefore the 
administration times of these drugs should be separated when given concurrently. The 
adult dose for adults is 8-12g daily po in 2 divided doses, and for paediatrics: 150-
300mg/kg/day in 2-4 divided doses (maximum 10g/day). The use of PAS is limited by its 
acceptability, as it is bulky and unpleasant to take [DOH, 2011]. 
 
2.3.10 Pyrazinamide 
PZA is bactericidal in an acidic environment (such as that found in bacterial 
macrophages) [Zhang et al 2003]. Many MDR-TB patients have chronically inflamed 
lungs, which also theoretically provide an acidic environment. It inhibits mycobacteria at 
concentrations of approximately 20mcg/ml [Chambers, 2004]. It has a sterilizing effect 
and is active against dormant bacteria, thereby allowing the treatment period to be 
shortened and playing a crucial role in the treatment of MTB.  
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PZA is a nicotinamide analogue with the molecular formula C5H5N3O, its structure is 
shown in Figure 1 below:  
 
Figure 1: Molecular structure of pyrazinamide [Zhang and Mitchison, 2003] 
 
The mode of action of PZA is poorly understood, although it is proposed that the drug is 
deaminated by PZA-susceptible strains of MTB into the active metabolite pyrazinoic 
acid, and that this metabolite disrupts membrane energetics and inhibits membrane 
transport function in MTB.  [Salfinger and Heifets, 1988; Zhang et al, 2003]. Early 
research by Salfinger and Heifets [1988] shows that for PZA, the minimum inhibitory 
concentration (MIC) is dependent upon pH. The MIC for MTB at pH 5.5 is 50mcg/ml, 
whereas at pH 5.95, the MIC is around 400mcg/ml.  
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PZA is only used in the treatment of mycobacterial infections and is used in combination 
with other anti-TB drugs. PZA is well absorbed from the gastrointestinal tract and widely 
distributed, reaching concentrations in the CSF equal to those in the plasma. It has a half-
life of 9-10 hours, and 4-14% of the drug is eliminated unchanged in the urine, the 
remainder as metabolites formed in the liver [Rossiter, 2010].  
The most important side effect noted is dose-related hepatotoxicity, as well as GIT side 
effects such as nausea, vomiting and diarrhoea, although these may be minimized if the 
drug is taken with meals. It may also cause hyperuricaemia (due to PZA inhibiting uric 
acid clearance) and this may be associated with non-gouty arthralgia. Liver function tests 
and serum uric acid levels should be regularly monitored. Photosensitivity, 
thrombocytopaenia and sideroblastic anaemia are rare. PZA is contraindicated in patients 
with porphyria, or those with severe hepatic damage, and should be used in caution in 
patients with gout, diabetes, renal impairment, and in patients who exhibit 
hypersensitivity to PZA, isoniazid, ethionamide or niacin. PZA inhibits urate clearance, 
and therefore allopurinol and probenicid dosages may need to be adjusted if used 
concurrently. When PZA is used with diuretics and ethambutol, there is an increased 
additive potential for serum urate levels to be elevated [Rossiter, 2010].  
The adult dose of PZA is 20-30mg/kg/day (maximum of 2g/day) [DOH, 2011]. For 
patients with renal impairment, the dose at the lower limit of the recommended range 
should be used, although if the patient’s GFR is less than 10ml/min the dose may be 
reduced by up to 50%. In paediatric patients the dose used is 15-30mg/kg daily (up to 
40mg/kg/day in TB meningitis, miliary and MDR-TB) [Rossiter, 2010]. 
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When PZA’s pharmacokinetics was studied under fasting conditions, with food, and with 
antacids, the Tmax was mostly around the 1-hour mark, indicating rapid absorption. The 
researchers discovered that the presence of food and antacids did not substantially affect 
the pharmacokinetics of PZA [Peloquin et al, 1998]. Tappero et al [2005] also reported 
good absorption of PZA in both HIV positive and HIV negative populations.  
Researchers in Canada studied the incidence of serious side effects of first-line anti-TB 
drugs in patients being treated for TB and found that PZA caused a substantially higher 
incidence rate of side effects like hepatotoxicity and rash than the other 3 drugs [Yee et 
al, 2003]. 
 
 2.3.10.1 Methods used in the determination of Pyrazinamide levels in plasma   
According to Peloquin [2002], the preferred methods used in the assay of 
antimycobacterial drugs are high-performance liquid chromatography (HPLC) and gas 
chromatography (GC) with UV detection or mass spectrometry.  
Most previous studies have either used HPLC with UV detection, or LC-MS to determine 
the levels of PZA in plasma.  
Unsalan et al [2006] used HPLC to assay the plasma levels of PZA, INH and rifampicin 
in 25 patients. They found the method to be simple, accurate, precise and reproducible, 
with the lower limit of quantification for PZA at 1.5mg/L and noted that many of the 
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levels were found to be subtherapeutic. Revankar et al [2013] also used HPLC to 
determine PZA levels in human plasma. They found it sensitive and selective.  
Chaitanya Krishna et al [2012] outlined their method for determining PZA levels in 
individual dosage forms and fixed-dose combinations. They used reverse phase liquid 
chromatography to separate the compounds, and a triple quadrupole mass spectrometer 
with electron spray ionization in the positive mode for ion detection. They describe this 
method as simple and selective.  
Shah et al [2012] used a similar method; also using reverse-phase liquid chromatography 
and a triple quadrupole mass spectrometer with electrospray ionization in the positive 
mode. They validated this method over a wide range of concentrations and found it to be 
sensitive and selective. 
Gong et al [2009], developed and validated a method of simultaneously analyzing the 
levels of PZA and ethambutol in human plasma using LC-MS. Their method utilized a 
HPLC system coupled with a triple quadrupole mass spectrometer using an atmospheric 
pressure chemical ionization source and operating in positive mode. They found their 
method to be rapid and robust, with a short run-time. Zhou et al [2013] also successfully 
used a LC-MS with a HILIC (hydrophilic interaction liquid chromatography) column to 
quantify PZA levels in a TDM study. 
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2.3.10.2 Pyrazinamide pharmacokinetic data from the literature     
Table 3: Population pharmacokinetic parameters for pyrazinamide in healthy subjects-mean (SD):  
Population:        Dose:  Cmax (mcg/ml):    Tmax (hr):    T1/2 (hr): AUC (mg.hr/L): Analysis:  Reference: 
9 Healthy       27mg/kg  38.7(5.9)        1                9.6(1.8) 520(101)  HPLC with    Lacroix et al, 1989 
adults             fluorimetry 
24 Healthy       1,5g           29.21(4.35)           1,17(0.41)    9.58              415.46                          HPLC-UV Peloquin et al, 1997  
adult males 
14 Healthy     30mg/kg 53.4        1.43   673   GCMS       Peloquin et al, 1998 
adults (fasting) 
 14 Healthy     30mg/kg 52.1        1.71   680   GCMS       Peloquin et al, 1998 
adults (fasting) 
14 Healthy     30mg/kg 45.6                   3.09   687   GCMS       Peloquin et al, 1998 
adults (after high-fat meal) 
14 Healthy     30mg/kg 55.7                   1.43   628    GCMS       Peloquin et al, 1998 
adults (with antacid) 
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Table 4: Population pharmacokinetic parameters for pyrazinamide in TB patients-mean (SD):  
Population:        Dose:  Cmax (mcg/ml):    Tmax (hr):    T1/2 (hr): AUC (mg.hr/L): Analysis:  Reference: 
18 HIV+  22-44mg/kg  34.0 (18.1)        3.7 (1.7)          -        411 (382)  HPLC-UV  Graham et al, 2006  
children 3 x weekly 
9 HIV–  22-44mg/kg 41.9 (22.9)        3.7 (1.7)           -          322 (240)  HPLC-UV    Graham et al, 2006   
children 3 x weekly 
15 Children   22-44mg/kg 27.5 (16.6)        3.5 (1.6)        -                   327 (335)  HPLC-UV    Graham et al, 2006     
0-4 years 
12 Children  22-44mg/kg 47.9 (17.7)        3.3 (1.4)        -                  416 (333)  HPLC-UV    Graham et al, 2006 
5 or over          3 x weekly 
 
6 Children       22-44mg/kg    44.3 (17.1)             3.7 (1.8)           -                     496 (407)     HPLC-UV    Graham et al, 2006 
>80% WFA    3 x weekly 
 
12 Children     22-44mg/kg     33.7 (23.2)             3.4 (1.4)           -    312 (261)     HPLC-UV    Graham et al, 2006 
60-80% WFA  3 x weekly 
 
9 Children       22-44mg/kg      35.4 (16.8)            3.2 (1.6)            -    337 (337)     HPLC-UV    Graham et al, 2006 
< 60% WFA   3 x weekly 
 
47 HIV+          2g daily     42.17(11.29)         2.31(0.98)      9.05(4.12)        290.76     HPLC        Perlman et al, 2004 
adults  
 
24 HIV+    2.5g intermittent   52.81(17.58)       2.73(1.51)      9.04(3.94)  366.64(107.25)        HPLC          Perlman et al, 2004 
adults  
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Contd… 
Population:        Dose:  Cmax (mcg/ml):    Tmax (hr):    T1/2 (hr): AUC (mg.hr/L): Analysis:  Reference:   
 
40 Children   30mg/kg/day     43.43(6.74)         2.25(0.77)      7.78(1.3) 496.11(138.15)     HPLC-UV         Arya et al,  2006  
                   
 
71 HIV+            1,5-2g 49.9     -       -                     -                                GC-MS        Chideya et al, 2009 
adults  
CD4>200  
 
84 HIV+           1.5-2g      46.9                  -                         -   -     GC-MS             Chideya et al, 2009 
adults  
CD4<200 
 
70 HIV-            1.5-2g      52.3                  -                         -                     -     GC-MS            Chideya et al, 2009 
adults 
 
  
141 Mostly                      
HIV- adults  35.7mg/kg/day      52,7                          2 5,9 499,7     HPLC-UV        McIlleron et al, 2006 
                                    
18 Adults with  32,5         45,5                          1  409     HPLC            Ruslami et al, 2009 
Type 2 diabetes 
 
18 Adults without  32,2         47                             1,5  468(     HPLC            Ruslami et al, 2009 
Type 2 diabetes 
 
 
 
 
 
 
 
 
30 
 
Contd… 
Population:        Dose:  Cmax (mcg/ml):    Tmax (hr):    T1/2 (hr): AUC (mg.hr/L): Analysis:  Reference:   
11 Children  
with TB         25mg/kg        42.4 (3.3)                  1.7 (0.2) 9.3 (1.3) 561 (99)     UV-spec          Gupta et al, 2007 
 
11 Children  
with TB         15mg/kg       38.6 (3.9)                   1.8 (0.1) 10.5 (2.3) 515 (89)     UV-spec          Gupta et al, 2007 
 
7 Children  
 with TB     31.9mg/kg       49.4 (2.8)                   2 7.8 (1.1) 435.0 (44.2)     UV-spec              Roy et al, 2012 
 
13 Children  
with TB      28.1mg/kg       41.7 (1.2)                   2 6.6 (0.6) 316.6 (20.7)     UV-spec              Roy et al, 2012 
 
14 HIV+  
Adults  
with TB                1,5g      32.1 (8.8)                   -  7.4 (1.6) 350 (111)     HPLC      Choudhri et al, 1997 
Contd… 
 
15 HIV-  
Adults  
with TB     1,5g       33.1 (8.2)                  -  6.9 (2.1) 382 (143)     HPLC      Choudhri et al, 1997 
 
11 Adults  
with TB  
and diarrhoea    1,5g      33.9 (9.0)                   -            7.8 (1.9) 407 (148)    HPLC      Choudhri et al, 1997 
 
18 Adults 
with TB 
without diarrhea   1,5g      31.7 (8.1)           -  6.7 (1.8) 336 (103)    HPLC     Choudhri et al, 1997 
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Contd… 
Population:        Dose:  Cmax (mcg/ml):    Tmax (hr):    T1/2 (hr): AUC (mg.hr/L): Analysis:  Reference:   
13 Adults       29.9mg/kg      55.9                          1.33 - 373.2    HPLC     Taylor and Smith, 1998 
with TB 
and AIDS 
 
14 Adults       29.9mg/kg      56.9                          1.36 - 385.3    HPLC Taylor and Smith, 1998  
with TB 
without AIDS 
 
59 Adults 1,5-2g      48.7  2 9.19 385    GCMS Tappero et al, 2005 
with TB 
with HIV 
 
28 Adults  1,5-2g      55.5  2 7.41 424    GCMS Tappero et al, 2005 
with TB 
without HIV
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2.4 HIV/AIDS: 
2.4.1 Introduction: 
Human Immunodeficiency Virus is a type of retrovirus, which infects cells in the host’s immune 
system, and destroys them or impairs their ability to fight infection. As a result of this, the host’s 
immune system may become incapable of fighting off infections and the patient may succumb to 
an illness that he or she would normally be able to fight off. Such infections are called 
“Opportunistic Infections”. HIV infection causes the syndrome known as AIDS (or Acquired 
Immune Deficiency Syndrome). The virus may be transmitted in the following ways; through 
unprotected sexual intercourse (anal or vaginal) through the transfusion of contaminated blood, 
through the sharing of contaminated needles or between a mother and her infant during 
pregnancy, childbirth or breastfeeding [WHO, 2013d]. 
 
2.4.2 Common opportunistic infections: 
As a patient’s CD4 count decreases, he/she will become more and more susceptible to infections. 
The conditions that most often affect HIV positive patients in South Africa include TB 
(pulmonary and extra-pulmonary), sepsis, pneumonia, oral and oesophageal candidiasis, herpes 
Zoster, Kaposi’s sarcoma, crytococcal meningitis, pneumocystis pneumonia, toxoplasmosis and 
cytomegalovirus [Wilson et al, 2008]. 
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2.4.3 Effects of HIV infection on the GIT: 
Most HIV positive patients experience gastro-intestinal tract (GIT) symptoms or disease at some 
stage. These include odynophagia or dysphagia, oesophageal candidiasis, apthous ulcers or 
herpes simplex ulcers and diarrhoea. Diarrhoea in HIV positive patients is common, and many 
patients will present with diarrheoa at some stage in their illness. Common causative organisms 
are Coccidia (Cryptosporidia, Microsporidia, Isospora belli and Cyclospora), bacteria 
(Salmonella, Shigella, Campylobacter and Clostridium difficile), mycobacteria (TB or MAC) and 
viruses (cytomegalovirus or HIV). Diarrhoea may also be caused by some antiretrovirals 
(particularly with Lopinivir/Ritonivir), antiTB drugs, or other drugs used to treat opportunistic 
infections. It may also be due to HIV associated enteropathy, which is associated with 
malabsorption [Wilson et al, 2008]. 
 
2.4.4 Hepatic HIV manifestations: 
Hepatic disease in HIV positive patients may be caused by hepatic viruses, the HI virus itself, 
opportunistic disease or medication. Antiretrovirals such as the NNRTI’s and protease inhibitors 
and anti-TB drugs such as PZA, isoniazid and rifampicin are associated with hepatotoxicity 
[DOH, 2009]. Co-infection with HIV and hepatitis B is common, and these patients are at an 
increased risk for chronic infection and chronic liver disease. They also are also more susceptible 
to drug-induced hepatotoxicity and may develop hepatitis B associated immune reconstitution 
inflammatory syndrome (IRIS) [Wilson et al, 2008:413-414]. Patients with hepatic disorders 
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may require dose adjustment of drugs including some ARV’s and antimycobacterials [Wilson et 
al, 2008]. 
 
2.4.5 Renal complications of HIV/AIDS: 
HIV infection is associated with both acute and chronic renal disease. The involvement of the 
virus on the kidneys may be direct or indirect and can result in acute tubular necrosis, acute 
interstitial nephritis, TB of the urological tract (kidneys, ureters, bladder), crystalluria (which 
may be associated with use of protease inhibitors), HIV-associated nephropathy (“HIVAN”), 
HIV immune complex kidney disease as well as other glomerulonephritidies. 
The dose of some of the nucleoside reverse transcriptase inhibitors may need to be decreased in 
patients with impaired renal function. Tenofovir commonly causes impaired renal function. 
Streptomycin and ethambutol are excreted by the kidney, and may need to be given in reduced 
doses [Wilson et al, 2008]. Patients with renal disorders may require dose adjustment of drugs 
including some antiretrovirals (ARVs) and antimycobacterials [Wilson et al, 2008]. 
 
2.4.6 Treatment of HIV/AIDS: 
HIV/AIDS is treated with antiretrovirals. The 3 classes used in South Africa are Nucleoside 
Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors 
(NNRTIs) and Protease Inhibitors (PIs). NRTIs prevent the conversion of viral RNA into 
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proviral DNA, while NNRTIs cause a conformational change in the enzyme reverse 
transcriptase, thereby inhibiting it. Protease inhibitors work by interfering with the function of 
the enzyme protease which cleaves viral polyproteins into functional proteins [Wilson et al, 
2008]. 
The regimens used for the treatment of HIV/AIDS in South Africa are summarised below: 
Table 5: Standardised National ART regimens for adults and adolescents [DOH, 2013]: 
Patients:       Regimen:    
  
All new patients needing treatment, including Tenofovir (TDF) +  
pregnant women  Emtricitabine(FTC) or Lamivudine  
(3TC) + Efavirenz (EFV)  
 
Patients with significant psychiatric co-morbidity or  TDF + FTC/3TC +  
where EFV might impair daily functioning (shift workers) Nevirapine (NVP) 
or patients in whom EFV use is contraindicated     
 
Adolescents       Abacavir (ABC) + 3TC + EFV 
 
Contraindication to TDF (renal disease or concurrent Zidovudine (AZT) + 3TC +  
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use of other nephrotoxic drugs)    EFV/NVP 
 
Contraindication to TDF and AZT (anaemia and renal  Stavudine (d4T) + 3TC + EFV/NVP 
disease or concurrent use of other nephrotoxic drugs)  
 
Contraindication to TDF and AZT and d4T    ABC + 3TC + EFV/NVP 
(anaemia and peripheral neuropathy and renal disease  
or concurrent use of other nephrotoxic drugs)   
Patients currently on d4T-based regimen   TDF + FTC/3TC + EFV 
 
Common side effects of ARV therapy include lactic acidosis (particularly stavudine), 
hepatotoxicity (particularly nevirapine), lypodystrophy/lipoatrophy (particularly long-term use of 
stavudine or protease inhibitors), psychiatric symptoms and hallucinations (efavirenz), 
gynaecomastia, peripheral neuropathy and rash that may progress to Steven-Johnson’s Syndrome 
in serious cases [Wilson et al, 2008]. 
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2.5 Tuberculosis and HIV/AIDS: A lethal combination:  
TB is the most common opportunistic infection that infects patients with HIV/AIDS and is a 
leading cause of death in these patients. The combination of TB and HIV/AIDS is lethal, and the 
diseases have common biologic, environmental and social etiologies. TB is the leading cause of 
morbidity and mortality in patients with HIV/AIDS, and is responsible for 1 in every 4 AIDS-
related deaths [WHO, 2013c]. The WHO suggests collaboration and integration between TB and 
HIV/AIDS control programs. This could improve diagnosis, treatment and outcome for patients 
co-infected with both diseases. Such programs require collaboration of policies at a national level 
and resources such as adequate staff, financial support, equipment and medication. [Friedland et 
al, 2007b:S121; WHO, 2012b].  
Treatment of patients co-infected with TB and HIV is complex. Not only does it involve patients 
having to take large amounts of medication, but also it is further complicated by three major 
issues: drug interactions, overlapping toxicities and immune reconstitution inflammatory 
syndrome [McIlleron et al, 2007]. 
Firstly, there may be interactions between antiretroviral and antimycobacterial drugs, and their 
effects on the body. Rifampicin causes the induction of CYP450 and p-glycoprotein [Wilson et 
al, 2008], this causes decreased levels of rifampicin (auto-induction), and other drug interactions 
(particularly with protease inhibitors and NNRTI’s) involving the CYP3A enzyme system 
[Coyne et al, 2009].  
Secondly, there is the issue of overlapping toxicities, with many of the drugs used to treat both 
conditions having similar side effect profiles. Skin rash, nausea, vomiting and hepatitis are 
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associated with all four first-line anti-TB agents as well as some of the antivirals (e.g.: efavirenz, 
nevirapine and some protease inhibitors) [McIlleron et al, 2007; Burman and Jones, 2001]. There 
is an increased risk of peripheral neuropathy with concomitant use of ethambutol, ethionamide or 
isoniazid with stavudine or didanosine, these patients should be monitored carefully and 
appropriate prophylaxis or treatment given simultaneously [Swart and Jones, 2009] 
Lastly, there is the issue of immune reconstitution inflammatory syndrome (IRIS), where a 
previously suppressed immune system is suddenly activated and may cause a paradoxical clinical 
deterioration. Immune reconstitution can cause a sudden worsening of symptoms in severely 
immunocompromised patients starting on ARV therapy, as the patient’s immune system’s start 
to recover and mount a response to the opportunistic infection [McIlleron et al, 2007; Burman 
and Jones, 2001]. Ideally, ARV initiation should be deferred until the patient is tolerating TB 
therapy (2-4 weeks). The patient should be carefully monitored during this time [DOH, 2013].  
Although there is limited evidence to suggest this, zidovudine may decrease levels of PZA 
[Swart and Jones, 2009]. Rifampicin is a potent CYP450 isoenzyme inhibitor and as such may 
decrease the plasma concentrations of abacavir, efavirenz, nevirapine, zidovudine and 
lopinivir/ritonavir. Where rifampicin is used with lopinivir/ritonavir, the lopinivir/ritonavir dose 
should either be doubled or extra ritonavir should be added [Swart and Jones (eds), 2009]. 
Streptomycin and tenofovir are both nephrotoxic agents and thus this combination should be 
avoided [Swart and Jones, 2009]. 
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2.6 Pharmacokinetics of the antimycobacterial drugs in HIV positive and HIV negative 
patients:  
Several authors have shown concern that patients with HIV may exhibit impaired absorption of 
antiTB drugs due to the possibility of malabsorption associated with retroviral disease [Graham 
et al, 2006; McIlleron et al, 2006; Gurumurthy et al, 2004a: 282 and 2004b]. This could possibly 
lead to sub-therapeutic levels, i.e. below the minimum inhibitory concentration and hence the 
spread of resistance.  
Berning et al [1992], report the case of a HIV-positive health care worker with suspected MDR-
TB. Low plasma concentrations as well as stool analysis indicated a malabsorption disorder. 
Patel et al [1995] report 2 HIV positive patients who suffered relapse with drug-resistant TB. 
These patients were evaluated for malabsorption, and while one of the patients showed no 
evidence of this, the other patient had chronic diarrheoa and an abnormal D-xylose absorption 
test. It is suspected that this may have been due to HIV enteropathy and that this may have 
contributed to subtherapeutic drug levels and consequently the development of drug-resistant TB 
in this patient.  
Evidence has been found of malabsorption of rifampicin and isoniazid in patients with HIV and 
diarrhoea and HIV and TB [Gurumurthy et al [2004a]. They investigated the urinary excretion of 
rifampicin and INH and their metabolites and found this was lower in both groups of HIV 
patients than in healthy subjects and HIV-negative TB patients. They also looked at the effect of 
HIV on the blood and urine levels of the first-line drugs. They found that HIV positive patients 
and HIV positive patients with TB, who had a history of diarrhoea and cryptosporidial infection, 
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exhibited decreased amounts of PZA and ethambutol excreted in the urine. They concluded that 
these patients had evidence of malabsorption and decreased bioavailability of these anti-TB 
drugs, and that this may be linked to poor treatment outcome [Gurumurthy et al, 2004b]. 
A group of investigators in Canada [Sahai et al, 1997] also studied the pharmacokinetics of the 4 
first-line drugs in HIV-positive patients who did not have TB.  They discovered that the total 
systemic drug exposure was 32% lower for rifampicin and 24% lower for PZA in HIV-positive 
than in HIV-negative volunteers. They concluded that HIV positive patients, especially those in 
the advanced stages of the disease, showed decreased plasma concentrations of rifampicin and 
PZA. Pinheiro et al in Brazil [2006] studied the absorption of rifampicin and INH in patients 
with and without TB.  Using urinary excretion of mannitol and lactulose as a measure of 
intestinal permeability, they found that almost all the patients had low levels of rifampicin or 
INH or both. They found however, that intestinal permeability was lower in the patients with TB 
than in those without TB, and suggest that intestinal absorption of these 2 drugs is decreased in 
patients with TB. Gupta et al [2007], reported no delayed absorption of PZA in children with TB, 
although there was wide interindividual variation of pharmacokinetics. 
No association was found between AIDS or gender and concentrations of the antiTB drug 
ethionamide [Conte et al, 2000], and Li et al [2004], who studied the use of therapeutic drug 
monitoring (TDM) in MDR-TB patients, discovered that although HIV positive patients were 
more likely to have decreased concentrations of ethionamide and ofloxacin, these differences 
were not statistically significant. 
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Graham et al [2006] studied the pharmacokinetics of ethambutol and PZA in children with TB to 
examine the impact of age, nutritional status and HIV infection. They used HPLC with UV 
detection and found low serum levels of the drugs in all of the participants. They found that PZA 
Cmax was lower in younger children (younger than 5 years) than in older, and lower in HIV 
infected children and those with severe malnutrition, although these differences did not reach 
statistical significance.  
Low serum levels have also been reported in patients without HIV/AIDS. Bento et al describe a 
case of malabsorption of anti-TB drugs in a young HIV negative patient who failed to improve 
clinically on oral anti-TB drugs. Analysis of the patient’s plasma showed very low or 
undetectable levels of the drugs, and hence malabsorption was suspected. The patient had no 
diarrhoea, normal serum albumin and investigations showed no GI abnormalities. The patient 
was switched to parenteral antimycobacterial therapy and began to improve clinically and 
radiographically, and was culture negative after three months. 
 Kimerling et al [1998], looked at the serum concentrations of the two most widely used anti-TB 
drugs; rifampicin and isoniazid, in HIV negative patients with TB. They found that 68% of 
patients showed low levels of INH and 64% had low levels of rifampicin. Although they did not 
find a statistically significant association between treatment failure and low serum 
antimycobacterial levels, they suggest that there may be a small population of patients for whom 
serum level monitoring might be appropriate and helpful, particularly in patients with drug-
resistant strains or in patients who do not achieve culture conversion.  
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Low serum concentrations of the antimycobacterial drugs ciprofloxacin, ethambutol, rifampicin 
and clofazimine were also found in HIV-infected patients with Mycobacterium avium Complex. 
The investigators found concentrations well below the expected normal ranges and concluded 
that this was most likely due to malabsorption [Gordon et al, 1993].  
It has also been found that MDR-TB patients had a significantly reduced intestinal absorptive 
area and significantly lower serum levels of rifampicin than patients with DS-TB and patients 
without TB [Barroso et al, 2009]. 
 
2.7 Aims of the study 
The aim of this study was firstly to determine PZA plasma concentrations using LC-MS, 
secondly to describe the pharmacokinetic parameters of PZA in patients with MDR-TB 
and patients co-infected with MDR-TB and HIV and thirdly to find out if HIV infection 
influences the pharmacokinetics of PZA in patients with MDR-TB. 
This was done in order to have a better understanding of the pharmacokinetics of this drug to see 
whether or not therapy could be optimized to provide effective antimicrobial cover while at the 
same time limiting dose-related side effects. This may help to improve patient outcomes and help 
prevent the spread of drug-resistant organisms.  
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2.8 Research questions:  
- Can LC-MS be used to assay the plasma levels of PZA in patients with MDR-TB? 
- What are the pharmacokinetic parameters for PZA in patients with HIV infection 
and in patients without MDR-TB infection? 
- Is there a significant difference between the pharmacokinetics of PZA in MDR-
TB patients with HIV infection and MDR-TB patients without HIV infection? 
2.8.1  Experimental hypotheses: 
2.8.1.1 LC-MS can be used to determine the plasma concentrations of pyrazinamide on 
patients with MDR-TB and patients with MDR-TB and HIV. 
2.8.1.2 The difference between the pharmacokinetics of pyrazinamide in HIV positive 
patients with MDR-TB, and the pharmacokinetics of pyrazinamide in HIV 
negative patients with MDR-TB is statistically significant. 
 
2.8.2 Null hypotheses: 
2.8.2.1 LC-MS cannot be used to determine the plasma concentrations of pyrazinamide 
on patients with MDR-TB and patients with MDR-TB and HIV. 
2.8.2.2 The difference between the pharmacokinetics of pyrazinamide in HIV positive 
patients with MDR-TB, and the pharmacokinetics of pyrazinamide in HIV 
negative patients with MDR-TB is not statistically significant. 
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2.8.3  General objectives:  
The general objectives of this study were to determine the plasma concentrations of PZA in 
blood samples of MDR-TB patients using LC-MS, to describe the pharmacokinetics of PZA at 
the doses used for the treatment of MDR-TB in South Africa, and to assess whether or not HIV 
infection influences the pharmacokinetics of PZA  
2.8.4 Specific Objectives:  
The first specific objectives was to determine the plasma concentrations of PZA in patients with 
MDR-TB and in patients with MDR-TB and HIV/AIDS, at specific time periods after the 
administration of oral PZA, using LC-MS to analyse the drug levels in the plasma. 
The second was to use these values in order to determine the following pharmacokinetic 
parameters for PZA: 
* The maximum plasma concentration (Cmax) 
* The time to reach the maximum plasma concentration (Tmax) 
* The elimination rate constant (Ke) 
* The half-life (T1/2) 
* The area under the plasma concentration vs. time curve from 0 to 24 hours (AUC0-24) 
* The area under the plasma concentration vs. time curve from 0 to infinity (AUC0-) 
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* The volume of distribution (Vd) 
* The clearance (Cl) 
* The mean residence time (MRT) 
* The absorption rate constant (Ka) 
The third objective was to compare these pharmacokinetic parameters in both populations using 
statistical analysis to determine if there were significant differences between them. 
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CHAPTER 3: 
RESEARCH METHODOLOGY 
 
3.1. Study site, design, and population:  
The study was conducted at the Brewelskloof Hospital (BKH) in Worcester, in the Western Cape 
province of South Africa. BKH is one of several South African hospitals specialising in the 
treatment of MDR-TB. The study was designed as a two-group, non-randomized 
pharmacokinetic study involving male and female HIV-positive (experimental group) and HIV-
negative patients (control group) both admitted for MDR treatment.  
3.2 Inclusion and exclusion criteria:  
Inclusion criteria were; signature of informed written consent form after aims, procedures, 
advantages and disadvantages for the study had been clearly explained to the patient in their first 
language, consent for HIV test if not already done, on treatment for MDR-TB for at least two 
weeks and aged between 18 – 65 years.   
Exclusion criteria were; patient request, history of any disease known to interfere with the 
pharmacokinetics of PZA, pregnancy, breast-feeding, intolerance to PZA, patients taking 
medicines known to interact with PZA and severe dehydration. 
The following information was recorded on a specially designed data collection form: weight, 
age, TB history, current therapy, other (non-TB) history and concurrent drug therapy (including 
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ART), time of medication administration, time of blood sampling, and any post-dosing 
complaints. 
 
3.3. Pyrazinamide dose and blood sampling: 
Study participants were kept nil per os from 12pm prior to the sampling day. On the morning of 
the sampling, baseline blood samples were taken for liver and renal function tests, 
haematological and virological tests. Patients were then given their usual dose of anti-TB 
medications, including PZA, and the time was noted. They were then allowed to eat and drink as 
normal.  All patients received single dosage forms (i.e. not fixed dose combinations) at a dose of 
25mg/kg.  
Blood samples for anti-TB drugs plasma concentrations were collected from an intravenous 
catheter placed in a forearm vein of each patient and placed in heparinized tubes before being 
centrifuged at 5,250 rpm for 5 minutes. Using a micropipette, the plasma was separated and 
stored at -80C until the date of analysis.   
 
3.4. Laboratory tests:  
Haematological tests (white blood cell count, red blood cell count, haemoglobin, and platelets), 
liver function (ALT, AST, GGT, and bilirubin) and renal function (urea and electrolytes, 
creatinine) tests were performed by PathCare Laboratories (Worcester). Immunological and 
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virological tests (HIV test, CD4 count, viral load) were conducted by the National Health 
Laboratory Services (NHLS) at Tygerberg Hospital.  
 
3.5 Determination of pyrazinamide plasma concentrations:  
PZA plasma concentrations were analysed using liquid chromatography-mass spectrometry at 
the Central Analytical Facility at the University of Stellenbosch in the Western Cape. 
The LC-MS analysis was performed using a Waters Accuity UPLC (ultra performance liquid 
chromatography) system connected to a Xevo triple quadrupole mass spectrometer (Waters, 
Milford, MA, USA). The column utilized was a Waters BEH Phenyl (1.7µm, 2.1mm x 100mm) 
at ambient temperature. The mobile phase used was 0.1 % formic acid in water (v/v) as solvent 
A, solvent B consisted of 0.1% formic acid in acetonitrile.  A flow rate of 0.3 ml/min was 
applied and an injection volume of 5 µl.  The gradient started at 98% solvent A for the first 0.1 
minutes followed by a linear gradient over 4 minutes to 60 % solvent B.  The column was 
washed for 1 minute at 100% solvent B and re-equilibrated for another 6 minutes at the starting 
conditions. 
The MS conditions were as follows: electrospray ionization in the positive mode was applied, the 
ion source and desolvation temperature were held at 100°C and 500 °C, respectively. The 
capillary voltage was 2.8 kV.  The desolvation gas at 1000 L/h and the cone gas was 50 L/h. The 
instrument was operated at multiple reaction monitoring (MRM) mode.  The MRM settings for 
PZA was 124>107 at collision energy 10 eV and cone voltage of 20 V.  Propanolol was used as 
internal standard and was monitored at an MRM of 260.3>183 at a collision energy of 20eV and 
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cone voltage of 18 V.  Waters MassLynx™ software was used for the data collection and 
processing.   
All chemicals used were obtained from Sigma-Aldrich (Cape Town, Western Cape). 
 
3.5.1 Preparation of standards 
The stock solution of 1 mg/ml was serially diluted with acetonitrile to obtain working solutions 
with the concentrations 10, 5, 1, 0.5, 0.1, 0.05 and 0.01 µg/ml.  These standards all contained 10 
ppm propanolol as an internal standard. 
 
3.5.2 Patient samples preparation 
To prepare the patients’ plasma samples for the LC-MS assay, trichloroacetic acid (30 µl) was 
added to 50 µl plasma followed by 170 µl internal standard solution (10 ppm propanolol in 
water). The mixture was vortexed for 1 minute, followed by centrifugation at 6000 g for 5 
minutes. [Jiang et al, 2011]. The supernatant was injected onto the LC-MS. Blank plasma was 
spiked with 1 and 5 ppm of PZA in triplicate to determine the recoveries and repeatability. The 
relative standard deviation was better than 7%. 
 
3.5.3 Pyrazinamide tablets 
PZA tablets (500mg, Batch No 1G029A, Sanofi Aventis, SA) were supplied by BKH and used as 
working standards.  
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3.6 Pharmacokinetic Analysis:  
Pharmacokinetic data for both groups was obtained by plotting the observed concentrations vs. 
time using GraphPad Prism 6 software (GraphPad Software, Inc, 
California).PZApharmacokinetic parameters were calculated based on the non-compartmental 
analysis. 
- The maximum plasma concentration (Cmax) was obtained directly from the plasma 
concentration-time profile  
- The time to reach the maximum plasma concentration (Tmax) was also obtained directly from 
the plasma concentration-time profile  
- The elimination rate constant (Ke) was calculated as –2.303 multiplied by the slope of the 
terminal log-linear phase of the plasma concentration-time profile  
- The half-life (T1/2) was calculated as 0.639/Ke  
- The area under the plasma concentration vs. time curve from 0 to 24 hours (AUC0-24) was 
calculated by the trapezoidal method using GraphPad Prism software   
- The volume of distribution (Vd) was calculated as Dose/(AUC x Ke)  
- The total body clearance (Cltot) was calculated as Dose/ AUC  
- The area under the plasma concentration vs. time curve from 0 to infinity (AUC0-∞) was 
calculated using the equation:  AUC0-∞ + Cplast / Ke  
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- The volume of distribution (Vd) was calculated as Dose/(AUC0-∞ x Ke)  
- The total body clearance (Cltot) was calculated as Dose/ AUC0-∞   
- The mean residence time (MRT) was calculated as: MRT= AUMC∞/AUC∞ 
Where AUMC∞ is the area under the momentum curve from zero to infinity calculated as 
AUMC∞ = AUMC+ Clast/Ke+(tlast x Clast)/ Ke  
AUMC is the area under the momentum curve and calculated as  
AUMC = (tici+ti-1 x ci-1)/2 x (ti-ti-1)  
 
3.7 Statistical analysis:  
The data that was obtained during the study was captured and stored using Microsoft Excel for 
Windows. Results were reported as medians and ranges, due to the fact that the sample size was 
relatively small and the results were fairly skewed. Comparisons were done using the 
nonparametric Wilcoxon Rank Sum test, using a level of significance of 0.01. 
Comparisons were done using the nonparametric Wilcoxon Rank Sum test, using a level of 
significance of 0.01. 
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3.8 Ethical considerations:  
This study was registered and approved by the University of the Western Cape’s ethics 
committee under the ethics clearance registration number 07/6/12. 
Permission was granted from the provincial department of health, as well as from the medical 
superintendent of Brewelskloof Hospital. The study was conducted according to the declaration 
of Helsinki and ICH guidelines. All patient information remains confidential. 
 
3.9 Limitations of the study methods  
The study was limited by the amount of staff and help that were able to assist in blood collection. 
It would have been preferable to be able to take more samples, and hence have more data points, 
especially in the first few hours after dosing, in order to obtain a more accurate pharmacokinetic 
picture. Although we were able to calculate all required pharmacokinetic parameters, differences 
and extreme values may have been over or under-estimated due to longer time intervals between 
data points. In addition, there was some difficulty in drawing blood from a few patients, which 
compromised the times slightly. The demographics of the patient population was limited by the 
number of patients available at that specific time – although attempts were made to recruit 
similar numbers of male and female, HIV positive and negative etc, this was not always possible, 
and subsequently resulted in an unbalanced sample size. The size of the study was limited by 
financial constraints, the evaluation of the true effect of HIV on the pharmacokinetics of PZA 
would require a higher number of patients in order to provide a statistically significant 
comparison.   
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CHAPTER FOUR: 
RESULTS  
 
 4.1 Demographic characteristics of the study population 
A total of 32 patients were enrolled in this study. Out of 32 patients, 9 were HIV positive (28%), 
and 23 (72%) were HIV negative. The median dosage of PZA and the median patient weight 
were comparable in both populations. 
Table 6: PZA dosage and patient weight: 
Patient population:  Median Dose: Median weight: Median Dosage/kg: 
Positive   1500mg  57.24kg  26.2mg/kg  
Negative   1500mg  51kg   24.4mg/kg  
Table 7: Demographics of study population:  
Study participants:   Number:   Percentage of total: 
Female    14    43.75% 
Male     18    56.25% 
Of the HIV - positive patients, 4 had a CD4 count greater than 200, with a median CD4 count of 
354.5.  
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5 of the HIV positive patients had a CD4 less than 200, with a median CD4 of 91. 
Table 8: HIV status of study population: 
HIV status:    Number:   Percentage of total: 
Negative    23    71.9% 
Positive, CD4 count > 200  4    12.5% 
Positive, CD4 count < 200  5    15.6% 
 
4.2  Pyrazinamide LC-MS analysis method 
The LC-MS method for the determination of PZA in human plasma was developed and 
validated. The validation of PZA LC-MS analysis was conducted by determining linearity, 
recovery, precision and accuracy, low limit of detection, low limit of quantification and 
specificity. 
 
4.2.1 Calibration curve and linearity 
The calibration curve was constructed by plotting the responses (peak areas) of PZA against the 
corresponding concentrations. The correlation coefficient (r²) of determination of PZA during the 
validation was greater than 0.99. 
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4.2.2 Precision and accuracy 
PZA recovery was determined by comparing peak areas from the plasma samples that spiked 
with PZA after extraction (i.e. calibration standards) with the corresponding PZA standard 
solutions. The percentage recovery of PZA was 84.1 ±6.7% at 1ppm spike and 74.7 ±4% at 10 
µg/ml. 
 
4.2.3 Lower limit of detection and quantification 
The lower limit of detection (LOD) of PZA plasma concentration that could be determined 
(taking into consideration the concentration which produces a signal to ratio of 3 that gives a 
measurable response from the MS detector) was 0.06 µg /ml. PZA lower limit of quantification 
(LOQ) in the plasma was found to be 0.10 µg /ml. 
 
4.2.4 Specificity 
There were no interfering peaks from the plasma components with the PZA peak, which was 
detected at a retention time of 9.68 minutes. Chromatograms showing the separation of PZA 
plasma extract are shown in Figure 2. 
 
 
 
 
 
 
 
56 
 
min
0.20 0.40 0.60 0.80 1.00 1.20 1.40 1.60 1.80 2.00 2.20 2.40 2.60 2.80 3.00 3.20 3.40 3.60 3.80 4.00 4.20 4.40 4.60 4.80 5.00 5.20 5.40 5.60 5.80
%
0
100
F1:MRM of 10 channels,ES+
260.2 > 183
PM_UWC_120802_24 
49 (35min) 
5.039e+006Propanolol
3.31
420214.75
5029621
min
%
0
100
F1:MRM of 10 channels,ES+
124 > 107
PM_UWC_120802_24 
49 (35min) 
2.769e+005Pyrazinamide
1.68
14982.35
275560
 
 
Figure 2:  Chromatogram of pyrazinamide plasma extract 
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4.3 Pharmacokinetic data 
The results obtained are summarized in the graphs and tables below. 
 
 
 
 
 
 
 
 
 
Figure 3: Concentration vs. Time profiles for HIV positive patients 
(Where the numbers 201054P, 201043P etc denote the study numbers allocated to HIV positive 
study participants.) 
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Figure 4: Concentration vs. Time profiles for HIV negative patients: 
(Where the numbers 201011N, 201012N etc denote the study numbers allocated to HIV negative 
study participants.) 
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Table 9: Median (range) Pharmacokinetic Parameters: 
 HIV Positive HIV Negative 
Cmax (mcg/ml) 40.04 (70.35) 32.34 (106.62) 
Tmax (hours) 2 (3) 4 (6) 
Ke 0.0664 (0.02658) 0.07183 (0.05998) 
T1/2 10.44 (3.95) 9.65 (8.44) 
AUC0-24 493.4 (912.1) 420.3 (1434.8) 
AUC(24-) 112.5 (362.96) 90.87 (1401.07) 
AUC(0-) 639.9 (1261.66) 507.83 (3060.57) 
Vd 24.87 (52.86) 29.74 (79.71) 
Cl 2.06 (4.61) 1.97 (6.45) 
MRT 8.60 (3.44) 8.63 (4.92) 
Ka 0.84 (0.66) 0.5 (1.02) 
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Table 9 above shows the median pharmacokinetic parameters for both HIV-positive and HIV-
negative patients. The median AUC(0-),, Cmax, half life, Ka and clearance values were higher in 
the HIV positive population than in the negative patients. 
HIV negative patients had a higher Tmax and Ke than positive patients, and showed an increased 
apparent volume of distribution. Mean residence times were similar in both populations.  
 
4.4 Statistical analysis 
The pharmacokinetic parameters of the two groups were compared using the nonparametric 
Wilcoxon Rank Sum test and the level of significance was set at 0.01.  
The findings of this analysis are shown in Tables 10, 11 and 12 below. 
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Table 10: The MEANS Procedure – All Patients (HIV negative and HIV positive): 
Variable N Mean Median SD Lower Quartile Upper Quartile Minimum Maximum 
 
AUC(0-) 32 775.8525 563.9200 631.1487 330.9300  1067.6200  175.1900  3235.7600 
Cmax 32 42.0916      32.4300 28.2230 18.9400  55.8800  9.800  116.4200 
Tmax 32 3.3438 4.0000 1.4053 2.0000  4.0000  1.0000  8.0000 
Ke 32 0.0711 0.0712 0.0151 0.0631  0.0773  0.0367  0.1063 
T1/2 32 10.2341 9.7400 2.4831 8.9650  10.9950  6.5200  18.8800 
Vd 32 39.5941 27.7150 25.2899 19.6850  62.4250  8.4200  88.1200 
Cl 32 2.7813 2.0150 1.8078 1.4050  4.6550  0.3100  6.7600 
MRT 32 8.4813 8.6150 1.1685 7.8500  9.2400  5.4500  10.3700 
Ka 32 0.6275 0.5700 0.2710 0.4100  0.8400  0.3000  1.32
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Table 11: The MEANS Procedure – HIV Negative Patients: 
Variable N Mean Median SD Lower Quartile Upper Quartile Minimum Maximum 
 
AUC(0-) 23 778.9996 507.8300 706.8521 303.9100  1056.2200  175.190  3235.7600 
Cmax 23 41.7035      32.3400      30.9646      17.8000        55.3100         9.8000       116.4200 
Tmax 23 3.7391        4.0000        1.2511       4.0000         4.0000  2.0000  8.0000 
Ke 23 0.0717 0.0718 0.0168 0.0630  0.0780  0.0367  0.1063 
T1/2 23 10.2570 9.6500 2.8079 8.8900  11.0100  6.5200  18.8800 
Vd 23 42.1039 29.7400 27.8790 18.2300  68.7000  8.4200  88.1200 
Cl 23 2.9355 1.9700 1.9438 1.4200  4.8600  0.3100  6.7600 
MRT 23 8.5217 8.6300 1.2557 7.5000  9.5700  5.4500  10.3700 
Ka 23 0.5609 0.5000 0.2547 0.3400  0.6800  0.3000  1.3200 
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Table 12: The MEANS Procedure – HIV Positive Patients: 
Variable N Mean Median SD Lower Quartile Upper Quartile Minimum Maximum 
 
AUC(0-) 9 612.1111 639.9 299.9956   443.5000  823.6000  249.9000  1162.0000 
Cmax 9 4.0833 40.0400 21.1738   30.1600  57.1600  15.0400  85.3900 
Tmax 9 2.3333 2.0000 1.3229   1.0000  4.0000  1.0000  4.0000 
Ke 9 0.0694 0.0664 0.0101   0.0631  0.0764  0.0563  0.0828 
T1/2 9 10.1756 10.4400 1.4851   9.0700  10.9800  8.3700  12.3200 
Vd 9 33.1800 24.8700 16.6303   24.7100  40.0600  11.2900  64.1500 
Cl 9 2.3878 2.0600 1.4252   1.3900  2.6600  0.6500  5.2600 
MRT 9 8.3778 8.6000 0.9683   8.4200  8.8200  6.1100  9.5500 
Ka 9 0.7978 0.8400 0.2469   0.6000  1.0000  0.4400  1.1000
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Table 13 : P-values for Wilcoxon tests   
                  Parameter:               P-value: 
 
Cmax                        0.5342 
Tmax                        0.0117 
Ke                        0.7397 
T1/2                        0.7397 
Vd                        0.6480 
Cl                        0.6780 
AUC(0-)                        0.4563 
MRT                        0.6780 
Ka                        0.0241 
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CHAPTER FIVE: 
DISCUSSION 
We were able to successfully fulfill all of our specific objectives as outlined in the beginning of 
our study. On the basis that previous authors had found evidence of altered pharmacokinetics of 
anti-TB drugs in certain patients, and that the pharmacokinetics of PZA has been incompletely 
characterised [Perlman et al, 2004], our study aimed to investigate and describe the 
pharmacokinetics of PZA in patients with MDR-TB and in patients with MDR-TB/HIV-
infection. There are very few studies in the available literature that utilise LC-MS to assay 
plasma levels of anti-TB drugs, and our study also aimed to investigate whether or not this 
method could be used to analyse PZA levels in the plasma.  
As highlighted earlier, there is evidence to suggest that some patients (both with and without 
HIV) might be subject to subtherapuetic levels of anti-TB drugs, possibly as a result of 
malabsoprtion or drug interaction, although this phenomenon seems to be more frequent in HIV 
positive patients than negative. Peloquin et al (1993), shared their experience of the analysis of 
over 1000 assays of anti-TB drug plasma levels over a six-month period at their facility in 
Colorado. Using HPLC or GC, they observed that most (70%) of the plasma concentrations in 
these samples were below normal reference values for 10 commonly used anti-TB drugs, 
including PZA (Peloquin, 1992). Peloquin and his team of researchers at the National Jewish 
Medical and Research Centre in Colorado have done much work in this field. They have 
conducted extensive analyses of serum drug levels of the TB drugs in both patients with and 
without TB, and their work has shown that the degree of TB-drug malabsorption differs in 
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different population groups. Although the exact causes of drug malabsorption are not well 
defined, they point out that it is reasonable to contemplate this phenomenon in patients co-
infected with HIV and TB. They propose that where malabsorption is suspected, serum drug 
levels taken at 2 hours post-dosing and 6 hours post-dosing may help to confirm this and also 
help distinguish between malabsorption and delayed absorption. They believe that low serum 
concentrations of the anti-TB drugs may be related to poor clinical outcome, but agree that there 
is much more research needed in this field and encourage researchers in other parts of the world 
to pursue and investigate this [Peloquin et al, 1999]. The cause of malabsorption in HIV positive 
patients may be linked to HIV-associated enteropathy [Wilson et al, 2008]. Pozniak et al [1999] 
also agreed that malabsorption should be suspected in any patients (HIV positive or negative) 
who fail to respond to therapy despite good adherence to treatment. 
Despite these findings, there are several conflicting reports that find the opposite to be true. 
Taylor and Smith [1998] investigated the pharmacokinetics of rifampicin, isoniazid and PZA in a 
small cohort of South African TB patients. They used HPLC to determine the plasma 
concentrations and concluded that HIV was not associated with lower concentrations of the 3 
drugs. Wilkins et al [2006] used HPLC with UV detection to study the pharmacokinetics of PZA 
in South African patients with DS-TB. They described a “one compartment model with first-
order absorption…and first-order elimination”.  The study revealed that although 2 distinct 
patient groups emerged from the data (“fast” absorbers and “slow” absorbers), these all fell 
within normal estimates, and they concluded that the pharmacokinetics of PZA did not vary 
significantly between different patient populations.  
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Several other researchers also failed to prove an association between AIDS and TB drug 
malabsorption. Choudhri et al [1997] concluded that the presence of AIDS or diarrhoea did not 
influence the pharmacokinetics of PZA, rifampicin and isoniazid in Kenyan patients.  Conte et al 
[1999] reported that although plasma and intrapulmonary concentrations of PZA were lower in 
non-TB-infected AIDS patients than in healthy volunteers, this difference did not reach statistical 
significance. They found the concentrations of PZA in epithelial lining fluid to be far greater 
than the plasma concentrations, and hypothesise that these high concentrations in the lungs might 
be a reason for the success of the drug in the treatment of PTB. Perlman et al [2004], studied the 
pharmacokinetics of PZA in 100 patients co-infected with HIV and TB. They utilized HPLC and 
having defined a low cut-off concentration of 25mg/L for PZA, they found that low serum levels 
were uncommon. All of these studies were conducted in patients with DS-TB; we failed to find 
any studies in South Africa that examined the differences in patients with DR-TB.  
We were able to effectively establish and calculate the required pharmacokinetic parameters in 
both study groups by using the plasma concentration values found in our analysis. In our study, 
the median AUC(0-), Cmax, T1/2 and clearance values were higher in the HIV positive population 
than in the negative patients, although none of these differences were statistically significant. 
HIV negative patients had a higher Tmax than positive patients, and showed an increased apparent 
volume of distribution. Mean residence times were similar in both populations. Our findings 
supported the views of Taylor and Smith [1998], and Wilkins et al [2006] above in that we found 
no significant differences between the pharmacokinetic parameters of PZA in HIV positive and 
negative patients with MDR-TB. The only exception to this was with regards to Tmax (p=0.0117), 
indicating that HIV negative patients with MDR-TB took significantly longer to reach maximum 
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concentrations of PZA in the plasma. However, the importance of this finding may be over-
estimated in this study due to the logistical limitations affecting the number of sampling times. 
PZA is rapidly absorbed, with Tmax often occurring around 1 hour [Peloquin et al, 1998]. More 
samples in the first 2 hours would have been possible with more resources and this could have 
painted a more accurate picture of the pharmacokinetic profiles, and therefore of the parameters 
that were calculated.  
Although there was a difference in Ka between the 2 populations, with HIV positive patients 
having a higher level than HIV negative, this difference did not quite reach statistical 
significance at the 0.01 level (p=0.0241). For PZA, Peloquin suggests a target Cmax of 20 to 40 
mcg/ml after a 25 mg/kg daily dose [Peloquin, 2002]. In our study, HIV positive patients had a 
median dose of 26.2mg/kg/day and a median Cmax of 40.04mcg/ml. HIV negative participants 
had a median daily dose of 24.4mg/kg with a median Cmax of 32.34mcg/ml. Hence, both groups 
of patients in our study achieved Cmax values within the desired range. In a study in Botswana by 
Tappero et al [2005], the influence of HIV on the serum concentrations of the antimycobacterial 
drugs was investigated. It was found that although low serum levels of rifampicin, isoniazid and 
ethambutol were common, PZA was well absorbed. They defined a low Cmax as less than 
35mcg/ml and a very low Cmax as 20mcg/ml. They found that HIV-positive patients had longer 
half-lives for PZA than HIV-negative patients, and this is in agreement with our findings. 
Although PZA levels were lower in the HIV-positive group in their study, the levels still fell 
within normal ranges. Since treatment for drug resistant TB is limited by the decreased 
effectiveness and toxicity of the second-line agents [Kahana, 1996], it makes sense that we 
investigate the available drugs fully, and ensure that they reaching therapeutic levels in the 
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serum, while limiting their toxic side effects. TDM involves the use of serum concentrations to 
adjust a patient’s dose to obtain a desired serum concentration (ideally one which is therapeutic, 
while minimizing side effects). While TDM is a useful tool, its use is limited by the fact that it is 
logistically expensive. Yew [2001], points out the usefulness of TDM in the management of TB, 
particularly in patients with poor clinical outcomes and patients in whom subtherapeutic drug 
levels may occur. He also highlights the usefulness of TDM in TB therapy when there is the 
possibility of drug-drug interactions and drug-disease interactions. This may be especially 
pertinent with the use of rifampicin, a potent cytochrome P450 inducer or in patients with hepatic 
or renal impairment, or those with other disease states that might influence drug kinetics, such as 
HIV. Mehta et al [2001] identified subtherapeutic levels of rifampicin in patients who were slow 
to respond to standard anti-TB treatment. After increasing their dose to reach a therapeutic 
plasma level, all patients showed a clinical and mycobacteriological response. The authors 
suggest that such interventions should be considered in patients with HIV, malnutrition, known 
GI or malabsorptive disease, and hepatic or renal disease. 
Peloquin [2004] explains that although there are logistical difficulties in implementing TDM for 
TB patients, it may help to maximize therapy in patients with TB and MDR-TB and in particular 
in patients for whom the published dosing guidelines do not elicit the necessary serum 
concentrations or clinical response. He expresses concern over patients who exhibit 
malabsorption of the anti-TB drugs, and suggests in these cases, that TDM might be useful in 
helping to optimize therapy and minimize treatment failures [1998].  He also makes some 
pertinent observations about the doses of anti-TB drugs, saying that in some patients, doses 
above the “normal” ranges may be needed, and that well-timed serum drug level observations 
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may help the practitioner to establish the correct dose for an individual patient who may be 
failing treatment due to subtherapeutic serum concentrations [2001]. 
It is inadequately studied whether or not low levels of the anti-TB drugs impact on a patients’ 
clinical outcome. Chideya et al [2009], looked at the pharmacokinetics of the first-line drugs and 
how they related to treatment outcomes, in 225 Botswanan patients, most of which were HIV-
positive. Low levels were found for 84% of patients for rifampicin, 37% for isoniazid, 39% for 
ethambutol and 5% for PZA. Of the four drugs, only low PZA level was associated with poor 
treatment outcomes in both HIV positive and negative patients. Positive HIV status with CD4 
count less than 200 was also related to poor treatment outcome, and they concluded that patients 
with a low PZA Cmax were 3 times more likely to develop poor treatment outcomes than patients 
with a normal Cmax. Patients were dosed at 35mg/kg/day and low Cmax was defined as 
concentrations less than 35mcg/ml. 
Another study of TB patients in Botswana produced some interesting findings. HIV positive 
patients with a CD4 count less than 200 were found to have a higher risk of poor treatment 
outcome than those that were HIV negative or those that were HIV positive but had a CD4 count 
greater than 200 [Chideya et al, 2009]. Patients with a low PZA Cmax were 3 times more likely to 
have a poor treatment outcome than patients with a normal Cmax, and PZA Cmax was found to be 
significantly lower in patients with a CD4 < 200 than in patients with a CD4 > 200, regardless of 
the patient’s HIV status. Patients with good treatment outcomes showed PZA Cmax values in the 
higher ranges, while lower PZA Cmax values were associated with poor treatment outcome.  
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This study sheds important new light on the pharmacokinetics of PZA in MDR-TB patients. PZA 
plays a crucial role in the treatment of DS-TB and DR-TB due to the fact that it is active against 
dormant tubercule bacilli and high levels of MDR-TB are already prevalent in some parts of 
South Africa [Cox et al, 2010). With the cure rate amongst patients with MDR-TB known to be 
as low as 32% [Kritski et al, 1997] and the emergence of XDR-TB which is notoriously deadly 
and hard to cure, with mortality rates around 40% and cure rates as low as 22% 
[O’Donnell:2013], it is crucial that we gather as much information as possible, in an attempt to 
optimize treatment and curb the spread of the disease. 
Peloquin et al [1999], who have conducted extensive analyses on the anti-TB drug serum levels 
in different patient populations, agree that although the risk factors for, and extent of 
malabsorption is largely unknown, it is reasonable to suspect that it may occur in patients with 
HIV/AIDS, and may play a role in subtherapeutic serum drug levels. Whether or not these low 
serum levels translate to poor clinical outcomes is largely unknown, and he encourages fellow 
researchers to investigate this more fully. 
Our study also aimed to investigate whether or not LC-MS could be used to analyse PZA levels 
in the plasma. A LC-MS method for the determination of PZA in plasma was developed and 
validated in our study, with the validation having been conducted by determining linearity, 
recovery, precision and accuracy, low limit of detection, low limit of quantification and 
specificity. The method that was developed was linear, sensitive, specific, precise and accurate, 
and was therefore suitable for the quantitative analysis of PZA in our study. It was difficult to 
compare our results with previous studies, as there are not many studies using LC-MS to analyse 
PZA levels in the plasma, with most of the examples in the literature being HPLC and less 
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frequently, GC. Um et al [2007] had also developed a LC-MS/MS method for the determination 
of the TB drugs in plasma, and used this to evaluate serum levels in patients with TB. They 
found low concentrations of the antiTB drugs to be common, with rifampicin having the highest 
prevalence with 23.5% and PZA the lowest with 4.5%. Song et al [2007] were also able to 
develop a method for analyzing PZA using LC-MS. Our study successfully used LC-MS, with 
our plasma level analysis results being similar to those found in other studies using methods such 
as HPLC [Taylor and Smith, 1998; Wilkins et al 2006].  
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CHAPTER SIX: 
CONCLUSIONS AND RECOMMENDATIONS 
In conclusion, we were able to achieve the objectives set out for this study and our research was 
able to characterise the pharmacokinetics of PZA in both patients with MDR-TB and patients 
with MDR-TB and HIV. This was successfully achieved by developing and validating an LC-
MS assay method for the determination of PZA levels in human plasma, and we therefore accept 
our first experimental hypothesis. We found no evidence of a significant difference between the 
two population groups with regards to any of the pharmacokinetic parameters studied, the 
exception being Tmax, and therefore reject our second experimental hypothesis and accept the 
null hypothesis in this case.   
Our research was limited by a relatively small overall sample size, and an unbalanced 
distribution between the 2 patient groups, as well as the inability to compare our results with 
those in healthy volunteers. The lack of previous similar studies utilizing LC-MS also restricted 
our ability to compare our results with similar populations. Notably, the scope of this study did 
not extend to explore the influence of PZA plasma concentrations on clinical outcome, which is 
the ultimate goal and important measurable result for both the individual patients, and the 
epidemiology of the disease. This study also did not investigate the influence of HIV infection on 
fAUC/MIC ratio, which is again an important measurable endpoint.  
There is much more research needed in the area of pharmacokinetics of antimycobacterial drugs 
in MDR-TB patients, especially in South Africa. Even greater, is the need to explore these 
pharmacokinetics in the HIV positive population, as these patients make up a significant 
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proportion of our MDR-TB patient population in South Africa. Further investigation is required 
in order to establish if these patients are being exposed to subtherapeutic or toxic doses, and 
whether or not this has an impact on treatment outcome. 
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